TG Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $240,335 | $204,918 | $192,574 | $161,709 |
Gross Profit | 199,141 | 171,408 | 154,432 | 133,554 |
EBITDA | 21,674 | 28,109 | 51,693 | 32,692 |
EBIT | 28,029 | 51,626 | 32,630 | |
Net Income | 7,781 | 19,777 | 23,037 | 390,895 |
Net Change In Cash | 240,335 | 204,918 | 192,574 | 161,709 |
Free Cash Flow | 21,025 | -17,945 | 19,593 | -23,233 |
Cash | 482,575 | 442,209 | 79,148 | 74,081 |
Basic Shares | 157,281 | 160,062 | 159,366 | 160,997 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $616,287 | $329,004 | $233,662 | $2,785 |
Gross Profit | 515,573 | 290,518 | 219,531 | 2,520 |
EBITDA | 134,361 | 49,902 | 26,100 | -213,106 |
EBIT | 134,117 | 49,622 | 25,677 | -213,621 |
Net Income | 447,179 | 23,383 | 12,672 | -223,812 |
Net Change In Cash | 616,287 | 329,004 | 233,662 | 2,785 |
Cost of Revenue | -196,574 | |||
Free Cash Flow | -24,986 | -40,562 | -31,413 | -176,184 |
Cash | 79,148 | 179,894 | 92,933 | 102,304 |
Basic Shares | 161,412 | 160,336 | 148,508 | 135,411 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | $0.05 |
2026-03-31 | $0.18 |
2025-12-31 | $0.14 |
2025-09-30 | $0.16 |